Last reviewed · How we verify
GSK1363089
At a glance
| Generic name | GSK1363089 |
|---|---|
| Also known as | GSK1363089G, GSK1363089A |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer (PHASE1, PHASE2)
- A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (PHASE2)
- MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy (PHASE1, PHASE2)
- A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) (PHASE2)
- Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck (PHASE2)
- Study of GSK1363089 in Metastatic Gastric Cancer (PHASE2)
- A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors (PHASE1)
- A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |